TSVT   $3.62  14.56% Market Closed After Close 3.61 -0.28%

2Seventy Bio Inc
Last Events:

2023-08-09 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-09 Trend Power changed from medium strength to strong.

2023-08-05 Trend Power changed from slow to medium strength.

2023-07-29 Trend pattern changed from расширяющаяся формация to нисходящий клин.

2023-07-29 Trend Power changed from almost flat to slow.

2023-07-28 Trend pattern changed from канал to расширяющаяся формация.

2023-07-27 Trend pattern changed from расширяющаяся формация to канал.

2023-07-26 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 4
Target Price Mean 8.25
Mean unverified/preliminary 8.25 / 8.25
Target Price Low / High 2.00 / 15.00
Median / STD DEV 8.00 / 5.56
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy None
rsi None Sell Sell
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 None Buy Sell
ma50 ActivelyBuy None None
ma100 ActivelyBuy Buy Buy
Candlestick PatternNov. 22, 2024 Bullish Three Inside Up - pattern is a made up of three candlesticks. Big black candlestick appears on the first day in a downtrend. The second day body is engulfed by the body of the first day. A white candlestick on the third day with a higher close than the second day. Considered to be a bullish reversal pattern.
ISIN US9013841070
ceo Mr. William D. Baird III, M.B.A.
Website https://www.2seventybio.com
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.